Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

CAR-engineered Cell therapy for Cardiovascular diseases

Objective

CARDIO will develop a next-generation immunotherapy based on gene-engineered regulatory T cells (Tregs) to restore immune homeostasis during acute and chronic inflammation in cardiovascular disease. Myocardial infarction (MI), often caused by atherosclerosis (AS), is a leading cause of death in Europe—affecting one in seven women and one in six men. MI results from thrombotic occlusion following plaque rupture or erosion, leading to myocardial ischemia, cell death, and a self-perpetuating inflammatory response. This unresolved inflammation impairs tissue repair, drives adverse remodeling, and contributes to both acute and chronic heart failure (HF), with devastating impacts on patient quality of life and survival.

Given the heart’s negligible regenerative capacity, CARDIO will utilize Tregs to (i) suppress chronic inflammation within atherosclerotic plaques, preventing their rupture, and (ii) disrupt the acute inflammatory cycle post-MI to support myocardial healing. CARDIO Tregs will be derived from healthy donors as an allogeneic, virus-free gene-engineered “off-the-shelf” product. To enhance specificity and function, they will be equipped with chimeric antigen receptors (CARs) targeting myocardial (MYOCAR) and atherosclerotic (ASCAR) antigens. Upon antigen recognition, these CAR Tregs will secrete tolerogenic cytokines and suppress inflammatory macrophages and T cells—key drivers of fibrosis and plaque progression.

Using in vivo CRISPR screening and protein engineering, CARDIO will tailor Tregs to inflammatory niches, ensuring stability and effective immune modulation. The ultimate goal is to deliver the first cellular immunotherapy for reducing atheroprogression and improving post-MI recovery—transforming outcomes for patients and reducing cardiovascular mortality.

Fields of science (EuroSciVoc)

This project has not yet been classified with EuroSciVoc.
Be the first one to suggest relevant scientific fields and help us improve our classification service

Programme(s)

Topic(s)

Funding Scheme

HORIZON-RIA - HORIZON Research and Innovation Actions

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-HLTH-2025-01

See all projects funded under this call

Coordinator

UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT
Net EU contribution
€ 2 573 777,28
Address
JOSEF-SCHNEIDER-STRASSE 2
97080 WURZBURG
Germany
Region
Berlin Berlin Berlin
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 2 573 777,28

Participants (6)